The Exoxemis technology platform has the potential to change the paradigm
of infectious disease prevention and treatment by providing an alternative
mechanism of action to existing antibiotics and other anti-infectives.
Drug resistance poses a growing threat and there are few alternatives
for the prevention of serious and resistant infections.
A novel approach
Exoxemis’ MPO system offers an alternative platform from which
to build a new series of effective products based upon natural host defense
mechanisms. This novel approach is effective against bacteria, viruses,
fungi, molds, yeasts and spores and promises to both prevent and treat
infection without promoting resistance.
A unique mechanism of action
The MPO and EPO enzymes work by generating singlet oxygen as the active
microbicidal agent. These enzymes bind selectively to the cell membranes
of disease-causing organisms minimizing collateral damage to normal flora
and host cells.
The promise of a new paradigm
Exoxemis proprietary technology offers the medical profession new tools
to address the challenge of infection prevention and treatment.